- Home
- ELVN
as 06-20-2025 12:35pm EST
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 927.8M | IPO Year: | 2020 |
| Target Price: | $39.60 | AVG Volume (30 days): | 593.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.30 - $30.03 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Jun 9 '25 | Sell | $20.74 | 6,667 | $135,574.05 | 303,309 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jun 3 '25 | Sell | $20.03 | 7,500 | $150,219.75 | 977,688 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | May 27 '25 | Sell | $16.18 | 3,250 | $52,593.45 | 23,000 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | May 19 '25 | Sell | $16.31 | 5,000 | $81,533.50 | 977,688 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | May 19 '25 | Sell | $16.49 | 5,000 | $82,453.00 | 972,892 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | May 7 '25 | Sell | $19.19 | 6,667 | $122,578.86 | 303,309 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | May 1 '25 | Sell | $20.04 | 7,500 | $150,390.64 | 977,688 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | May 1 '25 | Sell | $20.04 | 7,500 | $150,415.36 | 972,892 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Apr 28 '25 | Sell | $18.90 | 3,250 | $60,737.55 | 23,000 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Apr 21 '25 | Sell | $16.37 | 5,000 | $80,365.82 | 977,688 |
Latest Enliven Therapeutics Inc. News
ELVN Breaking Stock News: Dive into ELVN Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data
MT Newswires
4 days ago
Enliven Therapeutics Closes Public Offering
PR Newswire
4 days ago
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
MT Newswires
7 days ago
Sector Update: Health Care Stocks Slide Late Afternoon
MT Newswires
7 days ago
Top Midday Gainers
MT Newswires
7 days ago
Enliven Therapeutics Prices $200 Million Public Offering of Common Stock, Pre-Funded Warrants
PR Newswire
7 days ago
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
MT Newswires
7 days ago
Enliven's Chronic Myeloid Leukemia Candidate Achieves MMR Rate in Phase 1 Trial
Compare ELVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.